R&D SpringWorks spins out of Pfizer on rare disease mission A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases.
News FDA advisers split on new kidney cancer use for Pfizer's Sut... Committee could not decide if Sutent can be used after the removal of a cancerous kidney.
News Pfizer sues J&J, alleging it blocked access to Remicade bios... J&J used anticompetitive tactics to prevent use of cheaper Inflectra
Views & Analysis Pharma 2022: big pharma will remain a constant Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
Partner Content Partner Content Have you seen the agenda for Social Media in Pharma? Updates on Social Media in Pharma
News CMS aims for broader GLP-1 access via federal programmes CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
